(Q36369275)

13 August 2017

1 reference

title

Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy (English)

1 reference

13 August 2017

3

H Ballentine Carter

1 reference

13 August 2017

Christopher A Warlick

series ordinal

1

1 reference

PubMed ID

16414495

13 August 2017

Mohamad E Allaf

series ordinal

2

1 reference

PubMed ID

16414495

13 August 2017

language of work or name

1 reference

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

51-57

1 reference

13 August 2017

1

1 reference

Impotence following radical prostatectomy: insight into etiology and prevention

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Lead time associated with screening for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Natural History of Early, Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Watchful waiting and factors predictive of secondary treatment of localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Radical prostatectomy versus watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Importance of posterolateral needle biopsies in the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.07.004

10.1016/J.UROLONC.2005.07.004

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16414495